Ampullary neoplasia accounts for under 1% of gastrointestinal cancers, incidence in young adults has risen over twenty years, and there has been little formal guidance. This AGA Clinical Practice Update supplies fifteen best-practice statements drawn from literature review and expert opinion — explicitly not a systematic review, and carrying no evidence grades.
The assessment advice is specific. Use a side-viewing duodenoscope, not a forward-viewing gastroscope, because visualisation and controlled biopsy of the ampulla are otherwise poor and biopsy near the pancreatic orifice risks pancreatitis. Take at least six biopsies, weighted toward ulcerated or indurated areas, because 20–40% of ampullary adenomas already contain malignancy. Add endoscopic ultrasound for staging and to define intraductal extension in anything being considered for endoscopic resection, unless the lesion is under 1 cm with no worrying features.
The resection statements draw a clear line. Lesions suited to endoscopic papillectomy have well-defined margins, are under 4–5 cm, are non-friable and soft to probing, and have intraductal extension of 1 cm or less. Beyond 1 cm of intraductal extension in a surgically fit patient, that is a surgical referral. Metastatic spread and invasion beyond the mucosa are absolute contraindications. Resect en bloc where feasible, avoid sphincterotomy beforehand because electrocautery artefact and bleeding compromise histology, and use prophylactic pancreatic duct stenting, rectal NSAIDs and high-volume lactated Ringer's to reduce post-papillectomy pancreatitis.
- Six biopsies minimum, from ulcerated and indurated areas — a single negative biopsy does not exclude malignancy in one in three of these lesions.
- Do not perform biliary or pancreatic sphincterotomy before papillectomy; it destroys the margin you need to read.
- Surveillance at 3, 6 and 12 months then annually for five years, with side-viewing duodenoscopy and biopsy of the resection scar.
- For adenomas over 3 cm resected piecemeal, or with positive margins, plan thermal ablation and ductography with review every 2–3 months until eradication is biopsy-confirmed.
- High-grade dysplasia, incomplete resection or suspected malignancy goes to a multidisciplinary meeting with surgery and oncology, not back to the endoscopy list.
Why it matters
One in three to one in five of these adenomas is already cancer, and the endoscopic assessment decides whether that is found before or after an incomplete resection.
Don't overread it
These are expert best-practice statements with no formal evidence grading — the AGA says so explicitly, because no systematic reviews underpin them.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free